SG11202109172TA - Human carbonic anhydrase 2 compositions and methods for tunable regulation - Google Patents

Human carbonic anhydrase 2 compositions and methods for tunable regulation

Info

Publication number
SG11202109172TA
SG11202109172TA SG11202109172TA SG11202109172TA SG11202109172TA SG 11202109172T A SG11202109172T A SG 11202109172TA SG 11202109172T A SG11202109172T A SG 11202109172TA SG 11202109172T A SG11202109172T A SG 11202109172TA SG 11202109172T A SG11202109172T A SG 11202109172TA
Authority
SG
Singapore
Prior art keywords
compositions
methods
carbonic anhydrase
human carbonic
tunable regulation
Prior art date
Application number
SG11202109172TA
Inventor
Vipin Suri
Celeste Richardson
Brian Dolinski
Abhishek Kulkarni
Mara Christine Inniss
Dexue Sun
Elizabeth Jane Weisman
Grace Y Olinger
Scott Francis Heller
Jennifer Leah Gori
Michelle Lynn Ols
Kutlu Goksu Elpek
Tucker Ezell
Michael Schebesta
Michelle Lois Fleury
Dhruv Kam Sethi
Original Assignee
Obsidian Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Obsidian Therapeutics Inc filed Critical Obsidian Therapeutics Inc
Publication of SG11202109172TA publication Critical patent/SG11202109172TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A61K39/001112—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A61K39/464412—CD19 or B4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/01—Hydro-lyases (4.2.1)
    • C12Y402/01001—Carbonate dehydratase (4.2.1.1), i.e. carbonic anhydrase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
SG11202109172TA 2019-03-08 2020-03-06 Human carbonic anhydrase 2 compositions and methods for tunable regulation SG11202109172TA (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201962815402P 2019-03-08 2019-03-08
US201962815399P 2019-03-08 2019-03-08
US201962826487P 2019-03-29 2019-03-29
US201962826443P 2019-03-29 2019-03-29
US201962835548P 2019-04-18 2019-04-18
US201962835552P 2019-04-18 2019-04-18
US201962860388P 2019-06-12 2019-06-12
PCT/US2020/021596 WO2020185632A1 (en) 2019-03-08 2020-03-06 Human carbonic anhydrase 2 compositions and methods for tunable regulation

Publications (1)

Publication Number Publication Date
SG11202109172TA true SG11202109172TA (en) 2021-09-29

Family

ID=72426473

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202109172TA SG11202109172TA (en) 2019-03-08 2020-03-06 Human carbonic anhydrase 2 compositions and methods for tunable regulation

Country Status (12)

Country Link
US (1) US20230026259A1 (en)
EP (1) EP3935159A1 (en)
JP (1) JP2022524081A (en)
KR (1) KR20210149251A (en)
CN (1) CN113966397A (en)
AU (1) AU2020235865A1 (en)
BR (1) BR112021017744A2 (en)
CA (1) CA3132840A1 (en)
IL (1) IL286132A (en)
MX (1) MX2021010840A (en)
SG (1) SG11202109172TA (en)
WO (1) WO2020185632A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3551221T1 (en) 2016-12-08 2022-04-29 Immatics Biotechnologies Gmbh Novel t cell receptors and immune therapy using the same
CN110506057B (en) 2017-02-17 2023-09-29 百时美施贵宝公司 ALPHA synuclein antibody and application thereof
AU2020290522A1 (en) * 2019-06-12 2022-01-20 Obsidian Therapeutics, Inc. CA2 compositions and methods for tunable regulation
WO2021050789A1 (en) * 2019-09-10 2021-03-18 Obsidian Therapeutics, Inc. Ca2-il15 fusion proteins for tunable regulation
WO2022060806A1 (en) * 2020-09-16 2022-03-24 Obsidian Therapeutics, Inc. Compositions and methods for expression of anti-bcma chimeric antigen receptors with small molecule-regulated il15 in t cells
AU2022369972A1 (en) * 2021-10-18 2024-05-02 Obsidian Therapeutics, Inc. Compositions and systems for regulation of function/abundance and delivery of polypeptide payloads
WO2024103166A1 (en) * 2022-11-14 2024-05-23 Walia Jagdeep Compositions and methods for treating creatine deficiencies
WO2024124311A1 (en) * 2022-12-16 2024-06-20 Recepta Biopharma S.A. Plp2-derived peptides, pharmaceutical compositions, methods and uses of thereof

Family Cites Families (164)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US494A (en) 1837-12-01 Steering wheel for ships
US7094A (en) 1850-02-12 Connecting trucks with car-bodies
US568A (en) 1838-01-09 Sphebometeb for
US8148A (en) 1851-06-10 Island
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4851341A (en) 1986-12-19 1989-07-25 Immunex Corporation Immunoaffinity purification system
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US4965197A (en) 1987-06-12 1990-10-23 Massachusetts Institute Of Technology Coryneform expression and secretion system
CA2032914A1 (en) 1989-12-26 1991-06-27 Peter C.K. Lau Use of bacterial lipoprotein amino terminus in fusion plasmids for in vivo expression of lipid modified polypeptides
WO1993018181A1 (en) 1992-03-13 1993-09-16 Cornell Research Foundation, Inc. Synthetic gene sequence for a signal peptide
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
EP0656946B2 (en) 1992-08-21 2010-03-31 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
WO1994025591A1 (en) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
AU1394497A (en) 1996-01-17 1997-08-11 Imperial College Innovations Limited Immunotherapy using cytotoxic t lymphocytes (ctl)
AU4818297A (en) 1996-10-16 1998-05-11 Johns Hopkins University, The Cytokine enhanced immunotherapy for brain tumors
US6348584B1 (en) 1996-10-17 2002-02-19 John Edward Hodgson Fibronectin binding protein compounds
DE69839147T2 (en) 1997-06-12 2009-02-19 Novartis International Pharmaceutical Ltd. ARTIFICIAL ANTIBODY POLYPEPTIDE
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
KR100316347B1 (en) 1998-09-15 2002-08-27 한미약품(주) Recombinant microorganisms expressing a fusion protein of Escherichia coli enterotoxin II signal peptide and fusion protein of human growth hormone and a method of producing human growth hormone using the same
US6407063B1 (en) 1998-10-02 2002-06-18 Ludwig Institute For Cancer Research Tumor antigens and CTL clones isolated by a novel procedure
CA2415902A1 (en) 2000-07-10 2002-01-17 Xencor Protein design automation for designing protein libraries with altered immunogenicity
US20040170955A1 (en) 2000-09-08 2004-09-02 Wadih Arap Human and mouse targeting peptides identified by phage display
US7575924B2 (en) 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
DE10057397A1 (en) 2000-11-18 2002-05-23 Hella Kg Hueck & Co Device for oil level measurement in internal combustion engine, particularly in road vehicle, has housing at base of which vertically extending, elongated damping container is fitted, which is connectable to oil feed
WO2002061131A2 (en) * 2000-12-04 2002-08-08 Bristol-Myers Squibb Company Human single nucleotide polymorphisms
US20030054374A1 (en) * 2001-03-07 2003-03-20 Ramanathan Chandra S. Polynucleotide encoding a novel human G-protein coupled receptor, HGPRBMY27
EP1436316B1 (en) 2001-04-30 2008-01-23 ZyStor Therapeutics , Inc. Subcellular targeting of therapeutic proteins
EP1395293B1 (en) 2001-05-14 2009-07-22 Gbp Ip, Llc Lentiviral vectors encoding clotting factors for gene therapy
US7629153B2 (en) 2001-08-02 2009-12-08 Research Development Foundation Methods and compositions relating to improved lentiviral vector production systems
RU2305708C2 (en) 2001-10-02 2007-09-10 Энститю Клейтон Де Ля Решерш Recombinant lentiviral vector, host cell transduced with lentiviral vector, methods for transduction and uses thereof
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
US20040230380A1 (en) 2002-01-04 2004-11-18 Xencor Novel proteins with altered immunogenicity
GB0202018D0 (en) 2002-01-29 2002-03-13 Sense Proteomic Ltd Tag and method
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
GB0217033D0 (en) 2002-07-23 2002-08-28 Delta Biotechnology Ltd Gene and polypeptide sequences
GB0220467D0 (en) 2002-09-03 2002-10-09 Oxford Biomedica Ltd Composition
EP1581056B1 (en) 2002-12-13 2010-07-21 Genetix Pharmaceuticals Inc. Therapeutic retroviral vectors for gene therapy
WO2004101751A2 (en) * 2003-05-08 2004-11-25 University Of Kentucky Research Foundation A modified rubisco large subunit ∈n-methyltransferase useful for targeting molecules to the active-site vicinity of ribulose-1, 5-bisphosphate
EP1641813B1 (en) 2003-07-03 2011-11-09 Avatar Biotechnologies, Inc. Methods for obtaining molecules with reduced immunogenicity
ATE448312T1 (en) 2003-09-26 2009-11-15 Merck Serono Sa GUIDE SEQUENCES FOR USE IN THE PRODUCTION OF PROTEINS
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
PL1732588T3 (en) 2004-04-05 2009-12-31 Univ California Modulation of nkg2d
US20060148009A1 (en) 2004-10-12 2006-07-06 Xencor, Inc. Prediction and assessment of immunogenicity
EP1757703A3 (en) 2005-08-24 2007-12-05 Medizinische Hochschule Hannover Self-inactivating retroviral vector
EP1757702A1 (en) 2005-08-24 2007-02-28 Medizinische Hochschule Hannover Self-inactivating gammaretroviral vector
US20070048285A1 (en) 2005-08-24 2007-03-01 Christopher Baum Self-inactivating retroviral vector
ES2536437T3 (en) 2006-01-05 2015-05-25 The Ohio State University Research Foundation MicroRNA based methods for stomach cancer diagnosis
CA2635616A1 (en) 2006-01-05 2007-07-19 Carlo M. Croce Microrna expression abnormalities in pancreatic endocrine and acinar tumors
ES2448491T3 (en) 2006-03-02 2014-03-14 The Ohio State University Research Foundation MicroRNA expression profile associated with pancreatic cancer
US20090131348A1 (en) 2006-09-19 2009-05-21 Emmanuel Labourier Micrornas differentially expressed in pancreatic diseases and uses thereof
WO2008054828A2 (en) 2006-11-01 2008-05-08 The Ohio State University Research Foundation Microrna expression signature for predicting survival and metastases in hepatocellular carcinoma
US20090181458A1 (en) 2006-12-04 2009-07-16 Thomas David Reed Tubulo-vesicular structure localization signals
US20090092974A1 (en) 2006-12-08 2009-04-09 Asuragen, Inc. Micrornas differentially expressed in leukemia and uses thereof
WO2008108998A2 (en) 2007-03-02 2008-09-12 Richmond Chemical Corporation Method to increase the yield and improve purification of products from transaminase reactions
US8093016B2 (en) 2007-05-21 2012-01-10 Danisco Us Inc. Use of an aspartic protease (NS24) signal sequence for heterologous protein expression
US8415096B2 (en) 2007-05-23 2013-04-09 University Of South Florida Micro-RNAs modulating immunity and inflammation
US20090099034A1 (en) 2007-06-07 2009-04-16 Wisconsin Alumni Research Foundation Reagents and Methods for miRNA Expression Analysis and Identification of Cancer Biomarkers
CN102083462B (en) 2007-08-03 2015-02-18 巴斯德研究院 Lentiviral gene transfer vectors and their medicinal applications
US9809797B2 (en) 2007-10-03 2017-11-07 National Institutes Of Health (Nih) U.S. Dept. Of Health And Human Services (Dhhs) Division Of Extramural Inventions And Technology Enhanced generation of cytotoxic T-lymphocytes by IL-21 mediated FOXP3 suppression
EP2225396A4 (en) 2007-11-30 2011-03-02 Univ Ohio State Res Found Microrna expression profiling and targeting in peripheral blood in lung cancer
WO2009100430A2 (en) 2008-02-08 2009-08-13 Asuragen, Inc miRNAs DIFFERENTIALLY EXPRESSED IN LYMPH NODES FROM CANCER PATIENTS
CA2717026A1 (en) 2008-02-28 2009-09-03 The Ohio State University Research Foundation Microrna signatures associated with human chronic lymphocytic leukemia (ccl) and uses thereof
EP2112235A1 (en) 2008-04-24 2009-10-28 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Compositions and methods for microRNA expression profiling of nasopharyngeal carcinoma
US8357511B2 (en) 2008-08-01 2013-01-22 The Regents Of The University Of Michigan Protein purification tags and uses thereof
WO2010018563A2 (en) 2008-08-12 2010-02-18 Rosetta Genomics Ltd. Compositions and methods for the prognosis of lymphoma
CN102439169B (en) 2008-11-13 2014-11-19 复旦大学 Compositions and methods for micro-rna expession profiling of colorectal cancer
WO2010066384A1 (en) 2008-12-10 2010-06-17 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Compositions and methods for micro-rna expression profiling of cancer stem cells
US20100260739A1 (en) 2009-03-09 2010-10-14 Bioatla, Llc Mirac Proteins
US8828718B2 (en) 2009-04-03 2014-09-09 Centre National De La Recherche Scientifique Gene transfer vectors comprising genetic insulator elements and methods to identify genetic insulator elements
EP2427577A4 (en) 2009-05-04 2013-10-23 Hutchinson Fred Cancer Res Cocal vesiculovirus envelope pseudotyped retroviral vectors
EP2427574A2 (en) 2009-05-08 2012-03-14 The Ohio State University Research Foundation Microrna expression profiling and targeting in chronic obstructive pulmonary disease (copd) lung tissue and methods of use thereof
US8399624B1 (en) 2009-06-25 2013-03-19 Esbatech, An Alcon Biomedical Research Unit Llc Acceptor framework for CDR grafting
CA2766907A1 (en) 2009-07-06 2011-01-13 Novartis Ag Self replicating rna molecules and uses thereof
MY161867A (en) 2009-09-10 2017-05-15 Biocon Ltd Novel fusion proteins and method of expression thereof
WO2011034622A2 (en) 2009-09-21 2011-03-24 The Board Of Trustees Of The Leland Stanford Junior University Inducible self-cleaving protease tag and method of purifying recombinant proteins using the same
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
WO2011062962A2 (en) 2009-11-17 2011-05-26 The Trustees Of The University Of Pennsylvania Smndelta7 degron: novel compositions and methods of use
WO2011076142A1 (en) 2009-12-24 2011-06-30 Fudan University Compositions and methods for microrna expession profiling in plasma of colorectal cancer
WO2011076143A1 (en) 2009-12-24 2011-06-30 Fudan University Compositions and methods for microrna expression profiling of lung cancer
EP2341145A1 (en) 2009-12-30 2011-07-06 febit holding GmbH miRNA fingerprint in the diagnosis of diseases
WO2011094683A2 (en) 2010-01-29 2011-08-04 H. Lee Moffitt Cancer Center And Research Institute, Inc. Method of identifying myelodysplastic syndromes
EP2354246A1 (en) 2010-02-05 2011-08-10 febit holding GmbH miRNA in the diagnosis of ovarian cancer
WO2011109726A2 (en) 2010-03-05 2011-09-09 Bioatla Llc Homologous multi-specific antibodies
WO2011113030A2 (en) 2010-03-11 2011-09-15 H.Lee Moffitt Cancer Center & Research Institute Human cancer micro-rna expression profiles predictive of chemo-response
US9314516B2 (en) 2010-05-04 2016-04-19 Cassian Yee Conditional superagonist CTL ligands for the promotion of tumor-specific CTL responses
GB201008682D0 (en) 2010-05-25 2010-07-07 Vib Vzw Epitope tag for affinity based applications
EP2576594B1 (en) 2010-05-30 2016-07-13 The Governing Council Of The University Of Toronto Mitochondrial penetrating peptides as carriers for antimicrobials
CA2800741C (en) 2010-05-30 2018-07-24 The Governing Council Of The University Of Toronto Mitochondrial penetrating peptides as carriers for anticancer compounds
WO2011157294A1 (en) 2010-06-16 2011-12-22 Universita' Degli Studi Di Padova Compositions for use in treating or preventing cancer, breast cancer, lung cancer, ovarian cancer, metastasis, heart failure, cardiac remodelling, dilated cardiomyopathy, autoimmune diseases, or diseases or disorders related thereto
CN103347894B (en) 2010-06-19 2017-05-10 纪念斯隆-凯特林癌症中心 Anti-GD2 antibodies
WO2012044933A2 (en) 2010-10-01 2012-04-05 1/4Board Of Regents, The University Of Texas System B and t lymphocyte attenuator marker for use in adoptive t-cell therapy
JP2014503198A (en) 2010-11-22 2014-02-13 カリダス・バイオファーマ，インコーポレーテッド Novel signal sequences that improve protein expression and secretion of recombinant enzymes and other proteins
EA027153B1 (en) 2010-12-09 2017-06-30 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Use of chimeric antigen receptor-modified t cells to treat cancer
ES2899186T3 (en) 2010-12-31 2022-03-10 Bioatla Inc Rapid antibody humanization
CA3179835A1 (en) 2011-01-18 2012-07-26 The Trustees Of The University Of Pennsylvania Compositions and methods for treating cancer
US9259432B1 (en) 2011-01-31 2016-02-16 Parminder J. S. Vig Composition and methods for targeted delivery of a therapeutic compound to the brain or spinal cord of a subject for treatment of neurodegenerative diseases
US20140113978A1 (en) 2011-05-01 2014-04-24 University Of Rochester Multifocal hepatocellular carcinoma microrna expression patterns and uses thereof
US20130042333A1 (en) 2011-05-06 2013-02-14 Jean-Gabriel JUDDE Markers for cancer prognosis and therapy and methods of use
ES2864765T3 (en) 2011-05-11 2021-10-14 Childrens Medical Center Modified Biotin Binding Protein, Biotin Fusion Proteins, and Applications
WO2012174452A1 (en) 2011-06-17 2012-12-20 Shire Human Genetic Therapies, Inc. Mitochondrial targeting and therapeutic use thereof
JP5965481B2 (en) 2011-07-15 2016-08-03 レオ ファーマ アクティーゼルスカブ MicroRNA profiling for diagnosis of cutaneous T-cell lymphoma (CTCL)
EP2751292A4 (en) 2011-09-01 2015-05-20 Allegro Diagnostics Corp Methods and compositions for detecting cancer based on mirna expression profiles
SG2014008809A (en) * 2011-09-21 2014-04-28 Hoffmann La Roche Co2 profile cultivation
SG11201401196WA (en) 2011-10-03 2014-05-29 Moderna Therapeutics Inc Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
CN104126009B (en) 2011-10-07 2019-05-10 国立大学法人三重大学 Chimeric antigen receptor
WO2013066678A1 (en) 2011-10-26 2013-05-10 Georgetown University Microrna expression profiling of thyroid cancer
WO2013063419A2 (en) 2011-10-28 2013-05-02 The Trustees Of The University Of Pennsylvania A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
WO2013091661A2 (en) 2011-12-23 2013-06-27 Aarhus Universitet Proteolytic resistant protein affinity tag
WO2013142034A1 (en) 2012-03-23 2013-09-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mesothelin chimeric antigen receptors
SE536936C2 (en) * 2012-04-23 2014-11-04 Rational Enzyme Mining Rem Ab Human carbohydrate II with increased physical stability
BR112014026740B1 (en) 2012-04-27 2022-10-04 Bioatla, Llc ANTIBODY, COMPOSITION, METHOD FOR DELIVERING AN ADCC-ENHANCED ANTIBODY, AND, USE OF AN ANTIBODY
CN104321425B (en) 2012-05-07 2018-08-10 株式会社Nkmax Method for inducing and expanding the natural killer cells from peripheral blood mononuclear cells
IN2014DN09417A (en) 2012-05-10 2015-07-17 Bioatla Llc
SG11201408697QA (en) 2012-06-28 2015-02-27 Univ Central Florida Res Found Methods and compositions for natural killer cells
EP2891661B1 (en) 2012-08-31 2019-01-16 University-Industry Cooperation Group of Kyung Hee University Mitochondrial targeting peptide
WO2014057484A1 (en) 2012-10-09 2014-04-17 Ramot At Tel-Aviv University Ltd. Peptides for the treatment of neurodegenerative diseases
AU2013359212B2 (en) 2012-12-12 2017-01-19 Massachusetts Institute Of Technology Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation
PL2931898T3 (en) 2012-12-12 2016-09-30 Le Cong Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains
WO2014093694A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes
CN113528577A (en) 2012-12-12 2021-10-22 布罗德研究所有限公司 Engineering of systems, methods and optimized guide compositions for sequence manipulation
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
KR20150105635A (en) 2012-12-12 2015-09-17 더 브로드 인스티튜트, 인코퍼레이티드 Crispr-cas component systems, methods and compositions for sequence manipulation
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
WO2014121005A1 (en) 2013-02-01 2014-08-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Retroviral vector packaging cell lines and methods of purifying and producing retroviral particles
US10344052B2 (en) 2013-03-14 2019-07-09 Health Research, Inc. Targeting peptides and uses thereof
EP2970997A1 (en) 2013-03-15 2016-01-20 Regents of the University of Minnesota Engineering plant genomes using crispr/cas systems
TWI654206B (en) 2013-03-16 2019-03-21 諾華公司 Treatment of cancer with a humanized anti-CD19 chimeric antigen receptor
CN115261411A (en) 2013-04-04 2022-11-01 哈佛学院校长同事会 Therapeutic uses of genome editing with CRISPR/Cas systems
EP2992020B1 (en) 2013-05-03 2020-01-15 Ohio State Innovation Foundation Cs1-specific chimeric antigen receptor engineered immune effector cells
US20150067922A1 (en) 2013-05-30 2015-03-05 The Penn State Research Foundation Gene targeting and genetic modification of plants via rna-guided genome editing
WO2015039100A1 (en) 2013-09-16 2015-03-19 The Trustees Of The University Of Pennsylvania Cd137 enrichment for efficient tumor infiltrating lymphocyte selection
GB201318347D0 (en) 2013-10-16 2013-11-27 Ucl Business Plc Retroviral vectors
WO2015060328A1 (en) 2013-10-25 2015-04-30 理研計器株式会社 Potentiostatic electrolytic gas sensor
WO2015080981A1 (en) 2013-11-27 2015-06-04 Baylor College Of Medicine Csgp4-specific chimeric antigen receptor for cancer
US20150191744A1 (en) 2013-12-17 2015-07-09 University Of Massachusetts Cas9 effector-mediated regulation of transcription, differentiation and gene editing/labeling
PL3102673T3 (en) 2014-02-03 2020-11-02 Sangamo Therapeutics, Inc. Methods and compositions for treatment of a beta thalessemia
EP3143138B1 (en) 2014-05-13 2022-03-23 BioAtla, Inc. Conditionally active biological proteins
JP6831777B2 (en) 2014-07-21 2021-02-17 ノバルティス アーゲー Treatment of cancer using the CD33 chimeric antigen receptor
RU2751660C2 (en) 2014-07-21 2021-07-15 Новартис Аг Treatment of malignant neoplasm using humanized chimeric antigen receptor against bcma
CA2955465A1 (en) 2014-07-21 2016-01-28 Novartis Ag Treatment of cancer using a cll-1 chimeric antigen receptor
JP6721568B2 (en) 2014-07-29 2020-07-15 セレクティスＣｅｌｌｅｃｔｉｓ ROR1 (NTRKR1)-specific chimeric antigen receptor for cancer immunotherapy
CA2958200A1 (en) 2014-08-14 2016-02-18 Novartis Ag Treatment of cancer using a gfr alpha-4 chimeric antigen receptor
CA2959786A1 (en) 2014-09-03 2016-03-10 Bioatla, Llc Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts
WO2016036973A1 (en) 2014-09-04 2016-03-10 The Trustees Of The University Of Pennsylvania Glypican-3 antibody and uses thereof
EP3198010B1 (en) 2014-09-26 2020-11-04 Baylor College of Medicine Glypican-3 specific chimeric antigen receptors for adoptive immunotherapy
CA2970370A1 (en) 2014-12-24 2016-06-30 Massachusetts Institute Of Technology Crispr having or associated with destabilization domains
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
WO2016164580A1 (en) 2015-04-07 2016-10-13 Novartis Ag Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
KR20170135957A (en) 2015-04-10 2017-12-08 펠단 바이오 인코포레이티드 A polypeptide-based shuttle agent for improving the transfection efficiency of a polypeptide cargo into the cytoplasm of a target eukaryotic cell, its use, method and kit
SG11201708516YA (en) 2015-04-17 2017-11-29 David Maxwell Barrett Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
CN108474009B (en) 2015-06-25 2022-10-04 阿迈瑞斯公司 Maltose-dependent degreddeterminants, maltose-responsive promoters, stabilized constructs and their use in the production of non-catabolic compounds
EP3313863B1 (en) 2015-06-29 2020-12-23 The Board of Trustees of the Leland Stanford Junior University Degron fusion constructs and methods for controlling protein production
EP3325504A1 (en) 2015-07-21 2018-05-30 Novartis AG Methods for improving the efficacy and expansion of immune cells
EP3347375B1 (en) 2015-09-10 2020-12-23 The United States of America, as represented by The Secretary, Department of Health and Human Services Anti-cd276 chimeric antigen receptors
WO2017175072A1 (en) 2016-04-08 2017-10-12 Feldan Bio Inc. Peptide shuttle based gene disruption
WO2017180587A2 (en) 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
WO2018045034A1 (en) 2016-08-30 2018-03-08 Promab Biotechnologies, Inc. Chimeric antigen receptors having gitr intracellular domain as co-stimulatory domain
CN110913954A (en) * 2017-03-03 2020-03-24 黑曜石疗法公司 Compositions and methods for immunotherapy
SG10202001869VA (en) * 2017-03-03 2020-04-29 Obsidian Therapeutics Inc Cd19 compositions and methods for immunotherapy
AU2020290522A1 (en) * 2019-06-12 2022-01-20 Obsidian Therapeutics, Inc. CA2 compositions and methods for tunable regulation

Also Published As

Publication number Publication date
IL286132A (en) 2021-10-31
US20230026259A1 (en) 2023-01-26
MX2021010840A (en) 2022-01-19
BR112021017744A2 (en) 2021-11-16
CN113966397A (en) 2022-01-21
WO2020185632A1 (en) 2020-09-17
JP2022524081A (en) 2022-04-27
KR20210149251A (en) 2021-12-08
AU2020235865A1 (en) 2021-09-23
EP3935159A1 (en) 2022-01-12
CA3132840A1 (en) 2020-09-17

Similar Documents

Publication Publication Date Title
IL286132A (en) Human carbonic anhydrase 2 compositions and methods for tunable regulation
IL268406A (en) Compositions and methods for the treatment of hemoglobinopathies
ZA202207394B (en) Compositions and methods for treating hemoglobinopathies
IL279467A (en) Compositions and methods for the treatment of hemoglobinopathies and thalassemias
IL284414A (en) Methods and compositions for the treatment of fabry disease
IL281015A (en) Methods and compositions for the modification of plants
ZA202101362B (en) Compositions and methods for treating the eye
IL287594A (en) Compositions and methods for the treatment of retinal degeneration
ZA202101342B (en) Compositions and methods for treating the eye
ZA202104737B (en) Methods and compositions for treating skin and hair disorders
IL288798A (en) Ca2 compositions and methods for tunable regulation
EP4171606A4 (en) Compositions and methods for the treatment of covid-19
EP3648756A4 (en) Statin compositions and methods for use in treating synucleinopathies
ZA202101361B (en) Compositions and methods for treating the eye
ZA202101360B (en) Compositions and methods for treating the eye
ZA202007183B (en) Compositions and methods for treating the eye
PT3684477T (en) Useful compositions for the cosmetic treatment of oily skin
EP3856147A4 (en) Methods and probiotic compositions for the treatment of bone disorders
EP3750529A4 (en) Composition for prevention and treatment of spinal cord injury
IL289687A (en) Compositions for the treatment of hair loss
ZA202100402B (en) Emulsion-based personal care compositions and methods for the same
IL281501A (en) Compositions and methods for treating cellulite
EP3852820A4 (en) Compositions and methods for treating bone injury
EP3743085A4 (en) Compositions and methods for treatment of spinal cord injury
EP3761988A4 (en) Compositions and methods for treating hyperproliferative skin disorders